Oxaliplatin and Topotecan in Advance Ovarian Cancer

• Status: Terminated
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

This phase II trial is studying how well giving oxaliplatin together with topotecan works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as oxaliplatin and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Oxaliplatin; Topotecan

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer

• Meets 1 of the following criteria for response to prior platinum-based therapy:

• Platinum-resistant disease, defined as a disease-free interval of < 6 months after prior platinum-based therapy OR progressive disease on a platinum-containing regimen

• Platinum-sensitive disease, defined as a disease-free interval of > 6 months after prior platinum-based therapy

• Measurable or evaluable disease: Measurable disease is characterized as lesions reproducibly measurable in 1 dimension; evaluable disease is defined as known disease with CA125 levels > 50 U/mL on 2 occasions >= 1 week apart

• Previously treated with a taxane and platinum-based regimen, only 1 prior platinum-based regimen, including IV or intraperitoneal consolidation, one additional non-platinum and non-topotecan chemotherapy regimen allowed

• Life expectancy >= 4 months

• Total bilirubin =< 1.5 times upper limit of normal (ULN)

• AST =< 2.5 times ULN (5 times ULN if liver metastases are present)

• Creatinine =< 1.5 times ULN AND creatinine clearance > 40 mg/dL

Exclusion criteria:

• No presence of any other active cancer

• No uncontrolled intercurrent illness, including the following:

• Infection

• Symptomatic congestive heart failure

• Unstable angina pectoris

• Cardiac arrhythmia

• No history of severe allergy to platinum compounds

• (Mild reaction (skin only) allowed provided a negative skin test is obtained)

• No history of allergic reaction to appropriate antiemetics (e.g., 5HT3 antagonists)

• Recovered from prior chemotherapy

• At least 2 weeks since prior radiotherapy and recovered

• At least 4 weeks since prior investigational drugs

• No prior radiotherapy to the whole pelvic field

• No unresolved sequelae resulting from any surgical procedures

• No concurrent colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) during topotecan infusion

• No concurrent participation in another investigational trial

• No other concurrent investigational agents

• No other concurrent anticancer therapy